NCPA, GNP name three finalists for Pruitt-Schutte Student Business Plan Competition
ALEXANDRIA, Va. — Teams of pharmacy students from three universities have been named finalists in the Good Neighbor Pharmacy National Community Pharmacists Association’s Pruitt-Schutte Student Business Plan Competition, NCPA announced Tuesday. The finalists are from Idaho State University College of Pharmacy, University at Buffalo College of Pharmacy and Pharmaceutical Sciences, and University of Oklahoma College of Pharmacy.
The Business Plan Competition is named to honor two champions of independent community pharmacy, the late Neil Pruitt Sr. and the late Joseph Schutte. The goal of the competition is to motivate pharmacy students to create a business model for buying an existing independent community pharmacy or developing a new pharmacy. Through this competition, NCPA is better able to prepare tomorrow’s pharmacy entrepreneurs for a successful future.
“The growing interest in independent pharmacy among students is extremely exciting," stated Robert Greenwood, NCPA president. "It is encouraging to see so many pharmacy students with an interest in exploring entrepreneurial opportunities in pharmacy through the competition."
“It is a meaningful way to promote independent community pharmacy ownership," added Steve Collis, president and CEO of AmerisourceBergen, whose Good Neighbor Pharmacy program is the primary sponsor of the competition. "The business plan competition offers the type of constructive, real-world experience that will provide students with the confidence and knowledge to become successful pharmacy owners."
Team members and the adviser for the three finalist teams will receive complimentary registration, travel and lodging to NCPA’s 113th Annual Convention and Trade Exposition in Nashville, Tenn., Oct. 8 to 12, where they will compete for first, second and third place in a live competition. For the recipient of first place, $3,000 will be given to the NCPA student chapter and $3,000 contributed to the school in the dean’s name to promote independent pharmacy. Second place will award $2,000 each to the NCPA student chapter and to the pharmacy school, and third place $1,000.
The competition is supported by Good Neighbor Pharmacy, Pharmacists Mutual Companies and the NCPA Foundation.
FDA approves Covidien painkiller
ST. LOUIS — The Food and Drug Administration has approved an opioid painkiller made by Covidien’s generic drug division, the medical supply company said.
Covidien said the FDA approved Mallinckrodt’s morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients.
"FDA approval of this drug represents a key component in palliative care treatment," Covidien CFO and interim president for pharmaceuticals Matthew Harbaugh said. "It is important that we are able to respond to the concerns of the hospice and palliative care community."
Amneal introduces generic versions of four popular drugs
BRIDGEWATER, N.J. — Generic drug maker Amneal has introduced four new drugs to the market, all available in tablet form.
The products, approved by the Food and Drug Administration, include:
Lorazepam tablets, a generic version of anxiety treatment Ativan, are available in 0.5-mg, 1-mg and 2-mg strengths, each offered in 100-, 500- and 1,000-count containers;
Meclizine HCl tablets, a generic version of antihistamine Antivert, are available in 12.5-mg and 25-mg strengths in 100-, 500- and 1,000-count bottles;
Promethazine HCl tablets, the generic equivalent of antihistamine Phenergan, are available in strengths of 12.5 mg in 100-count, 25 mg in 100- and 1,000-count and 50 mg in 100-count bottles; and
Venlafaxine HCl tablets, the generic equivalent of antidepressant Effexor, are available in five strengths: 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg, each in a 90-count bottle.
"We are very pleased with the addition of these four new products to Amneal’s portfolio and our continued aggressive growth," Amneal president Chirag Patel said. "Going forward, the pace will accelerate as we add several new dosage forms, introduce complex and unique products and realize the results of our dramatically expanded [research and development] team."